An anonymous director reports

MINDMED ANNOUNCES VOLUNTARY DELISTING FROM CBOE CANADA

Mind Medicine (MindMed) Inc. has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed's common shares will continue to be listed and tradable on the Nasdaq Global Select Market under the symbol MNMD, and Canadian shareholders can continue to trade their shares on Nasdaq.

The company believes that the trading volume of its common shares on Cboe Canada no longer justifies the expense and administrative requirements associated with maintaining this dual listing. MindMed's Nasdaq listing provides its shareholders with sufficient liquidity as Nasdaq accounts for approximately 95 per cent of its trading volume. The substantial savings in exchange fees, legal fees, and managerial time and effort to maintain a dual listing can be redirected to initiatives intended to generate shareholder value. The board of directors of the company has approved the voluntary delisting from Cboe Canada. In accordance with the Cboe Canada listing manual, Cboe Canada does not require shareholder approval of the voluntary delisting of MindMed's common shares as an acceptable alternative market will exist for the common shares on the date of delisting.

Following delisting from Cboe Canada, MindMed's shareholders can trade their common shares through their brokers on Nasdaq. As most brokers in Canada, including many discount and on-line brokers, have the ability to buy and sell securities listed on Nasdaq, MindMed's Nasdaq listing will continue to provide shareholders with the same accessibility to trade the company's common shares. Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade MindMed's common shares on Nasdaq. MindMed will continue to be a reporting issuer under applicable securities laws in all provinces and territories of Canada following the delisting of the common shares from Cboe Canada.

For answers to frequently asked questions about the voluntary delisting, please visit the FAQ section of MindMed's website.

About Mind Medicine (MindMed) Inc.

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Its mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. It is developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.

MindMed trades on Nasdaq under the symbol MNMD and currently trades on Cboe Canada (formerly known as the NEO Exchange) under the symbol MMED.

We seek Safe Harbor.